相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation
Eric Keil et al.
BLOOD (2014)
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
Amy M. Cook et al.
BLOOD (2014)
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
Chiharu I. Kobayashi et al.
BLOOD (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
Concetta Quintarelli et al.
LEUKEMIA RESEARCH (2014)
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
Paolo Gallipoli et al.
BLOOD (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1BCR-ABL-JAK2 Complex
Min Chen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
Sung O. Park et al.
PLOS ONE (2013)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
Christoph Walz et al.
BLOOD (2012)
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Florian H. Heidel et al.
CELL STEM CELL (2012)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML
Rajesh R. Nair et al.
LEUKEMIA RESEARCH (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Wolfgang Warsch et al.
BLOOD (2011)
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
Erik A. Nelson et al.
BLOOD (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Jorge Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
A. Samanta et al.
LEUKEMIA (2011)
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
Manuel Sobrinho-Simoes et al.
BLOOD (2010)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
Adam D. Shilling et al.
DRUG METABOLISM AND DISPOSITION (2010)
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
Andrea Hoelbl et al.
EMBO MOLECULAR MEDICINE (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors
D. K. Hiwase et al.
LEUKEMIA (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling
Andrew D. Wood et al.
BLOOD (2009)
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
Y. Hu et al.
LEUKEMIA (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance
S. Scott Perry et al.
BLOOD (2007)
Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells
Vladimir Jankovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Janus kinase 2: A critical target in chronic myelogenous leukemia
Ajoy K. Samanta et al.
CANCER RESEARCH (2006)
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
Dan Ye et al.
BLOOD (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Jak2 is involved in c-Myc induction by Bcr-Abl
SH Xie et al.
ONCOGENE (2002)
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl
YP He et al.
BLOOD (2002)
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
SH Xie et al.
ONCOGENE (2001)
The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl
XW Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
TL Holyoake et al.
BLOOD (2001)
分享论文
